Pro-Dex, Inc. (PDEX)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
$73.41+18.88%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
QuarterlyIQ Insights · PDEX
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 26.5% |
| Our one-year growth estimate | diamond | 5.5% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 21.0 percentage points more one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 25 industry peers
PDEX — earnings miss
Dated 2026-09-03
of this Form 8-K, as well as Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing. On September 3, 2026, Pro-Dex, Inc. (the “Company”) is issuing a press release announcing its financi…
Why it matters: Good news about the APM acquisition may mean successful integration. It could also bring in new revenue.
Watch forManagement says revenue or cost savings are up from the APM acquisition.
Also watch forManagement says there are problems or delays in getting benefits from the APM deal.
Why it matters: If the health care sector's revenue growth speeds up, it could benefit Pro-Dex. This may improve investor sentiment.
Supportive ifHealth care sector revenue growth is speeding up again. It is moving toward 10% or more.
Worry ifHealth care sector revenue growth slows below 5%.
Why it matters: Growing revenue shows the company is meeting its financial goals.
Supportive ifQ4 revenue exceeds $20M, showing continued growth from previous quarters.
Worry ifQ4 revenue falls below $19.95M, indicating a slowdown in growth.
Why it matters: Net sales growth is key to showing ongoing demand for the next generation handpiece.
Worry ifQ4 net sales growth below 15% year over year.
Less concerning ifQ4 net sales growth meets or exceeds 15% year over year.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$215 on $10,000 · ±2.2% | How much price usually moves either way. |
| Bad day | $514 loss on $10,000 · 5.1% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,741 loss on $10,000 · 37.4% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: A big drop would mean higher costs and problems. This could hurt investor trust.
Worry ifOperating income drops more than 15% from $3.1 million.
Less concerning ifOperating income stays the same or grows. This shows good cost management.
Why it matters: More revenue from APM means the company is growing and integrating well.
Supportive ifAPM revenue contribution exceeds $1 million in the next quarter.
Worry ifAPM revenue contribution remains below $500,000 in the next quarter.
Why it matters: Strong operating income growth shows good cost control and profit. Less than 5% growth may worry investors.
Supportive ifOperating income growth above 5% compared to the same quarter last year.
Worry ifOperating income growth falls below 5% compared to the same quarter last year.
Why it matters: Stable or growing operating income shows better control over costs. This means more money is made.
Supportive ifOperating income for Q3 shows growth or stability. This is compared to $3.1 million.
Worry ifOperating income falls more to $3.1 million.
Why it matters: A decline in net income could indicate rising costs or weakening demand.
Worry ifNet income for Q4 drops below $2.5 million.
Less concerning ifNet income for Q4 stays above $3 million.
Why it matters: If peers like Lilly or AbbVie show strong earnings, it may lift Pro-Dex's profile. It shows how the market views the sector.
Watch forLilly or AbbVie reports earnings growth above 15% year over year.
Also watch forLilly or AbbVie reports earnings decline of 5% or more year over year.
Why it matters: News about this deal shows how Pro-Dex is growing. It affects future growth.
Watch forLook for news on when the deal is done or major steps forward.
Also watch forNo updates or delays in the acquisition process.
Why it matters: Restating EPS guidance shows the company is sure about making money. It also shows they expect to grow.
Supportive ifManagement reaffirms EPS guidance for fiscal 2026 during the next earnings call.
Worry ifManagement lowers EPS guidance for fiscal 2026 during the next earnings call.